Dados do Trabalho

Título

SOBREVIDA EM 5 ANOS DE ACORDO COM SUBTIPO MOLECULAR DE 9,516 PACIENTES COM CANCER DE MAMA TRATADAS EM UM CENTRO DE REFERENCIA

Título em Inglês

5-YEAR SURVIVAL ACCORDING TO THE MOLECULAR SUBTYPE OF 9,516 BREAST CANCER PATIENTS TREATED IN A REFERENCE CENTER

Introdução

Breast cancer in Brazil has high mortality due to the large number of patients diagnosed and treated in advanced stages, due to lack of organized screening program and the long time between the diagnosis and initiation of treatment in the Unified Health System (SUS). For the 2020-2022 triennium, the National Cancer Institute (INCA) estimated 66 thousand new cases of breast cancer among Brazilian women. In the city of São Paulo, 5,350 new cases were estimated, with a gross rate of 80.81 / 100,000. The biomarkers (RE, RP, Her2 and Ki-67) in breast carcinomas allowed to subdivide into four subgroups: luminal A, luminal B, overexpression of HER2 and triple-negatives and greatly contributed to the specificity therapy with an impact on patient survival. The data about survival in SUS is scarce in the literature.

Objetivos

Objectives:
To assess 5-year survival in different molecular subtypes in 9,516 patients treated for breast cancer from January 2011 to December 2019 at Pérola Byington Hospital (PBH).

Métodos

The official database of PBH from January 2011 to December 2019 included 11,373 cases of breast cancer, based on that we proposed an observational, cross-sectional and retrospective study and we could include 9,516 patients treated for invasive breast cancer and that had data available to analyze overall survival according to the molecular type of the tumor, regardless of the tumor clinical stage.

Resultados

Discussion:
The luminal molecular subtype A (present in 24.7%) had better survival (92% in 5 years), the luminal subtype B was the most frequent, (32.8%) and the slightly lower survival, 88%. The ones that had the shortest survival, especially in the first 2 years, were the HER-2 sub types present in 17.5% and the triple-negative ones (25.1% of the patients). There are few data in Brazil evaluating the molecular subtypes and survival. The great number of triple-negative tumors is probably due to the fact that it was a population of untraceable women under the age of 50.

Conclusões

The molecular subtypes of breast cancer are important to guide therapeutic measures and predict the prognosis of patients. With the data obtained at Hospital Pérola Byington, it can be concluded that the Luminal A subtype are the ones with the best prognosis, while the Triple negative and Her 2 positive had higher mortality, especially in the first 2 years.

Palavras Chave

Breast cancer; molecular subtype; Unified Health System (SUS); survival breast cancer; Perola Byington Hospital (PBH).

Área

TUMOR CELL, MOLECULAR BIOLOGY, PREDICTIVE AND PROGNOSTIC FACTORS - Tumor cell, molecular biology, predictive and prognostic factors – other